Toronto Dominion Bank raised its holdings in Waters Co. (NYSE:WAT) by 11.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,876 shares of the medical instruments supplier’s stock after buying an additional 3,989 shares during the period. Toronto Dominion Bank’s holdings in Waters were worth $7,317,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in Waters by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 209,081 shares of the medical instruments supplier’s stock valued at $38,436,000 after buying an additional 1,448 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Waters during the third quarter worth about $3,446,000. Advisory Services Network LLC increased its position in shares of Waters by 6.0% during the second quarter. Advisory Services Network LLC now owns 1,145 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 65 shares in the last quarter. Nippon Life Insurance Co. acquired a new stake in shares of Waters during the third quarter worth about $819,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Waters by 46.8% during the third quarter. BNP Paribas Arbitrage SA now owns 54,218 shares of the medical instruments supplier’s stock worth $9,733,000 after purchasing an additional 17,280 shares in the last quarter. Institutional investors own 93.36% of the company’s stock.
In other Waters news, SVP Eugene G. Cassis sold 23,863 shares of Waters stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $197.53, for a total value of $4,713,658.39. Following the sale, the senior vice president now owns 15,100 shares of the company’s stock, valued at approximately $2,982,703. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joann A. Reed sold 1,386 shares of Waters stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $194.07, for a total value of $268,981.02. The disclosure for this sale can be found here. Insiders sold a total of 121,289 shares of company stock worth $25,383,542 in the last ninety days. 5.07% of the stock is owned by corporate insiders.
A number of analysts have recently commented on the company. Barclays lifted their target price on Waters from $188.00 to $193.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Janney Montgomery Scott raised their price target on Waters from $200.00 to $230.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Zacks Investment Research raised Waters from a “hold” rating to a “buy” rating and set a $211.00 price target on the stock in a report on Monday, October 23rd. William Blair reissued an “outperform” rating on shares of Waters in a report on Tuesday, January 23rd. Finally, Citigroup raised their price target on Waters from $190.00 to $223.00 and gave the stock a “neutral” rating in a report on Wednesday, January 24th. Twelve equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $203.75.
Shares of Waters Co. (NYSE:WAT) opened at $206.18 on Monday. Waters Co. has a twelve month low of $152.05 and a twelve month high of $220.20. The firm has a market capitalization of $16,398.12, a P/E ratio of 27.49, a price-to-earnings-growth ratio of 2.47 and a beta of 0.88. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.10 and a quick ratio of 1.97.
Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, January 23rd. The medical instruments supplier reported $2.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.07. Waters had a return on equity of 24.70% and a net margin of 0.88%. The company had revenue of $687.28 million for the quarter, compared to analyst estimates of $671.98 million. During the same quarter in the previous year, the company earned $2.21 EPS. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. equities research analysts forecast that Waters Co. will post 8.16 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/19/toronto-dominion-bank-has-7-32-million-holdings-in-waters-co-wat.html.
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.